Clinical Trials Logo

Clinical Trial Summary

Some of the fat (triglyceride) from the food humans eat gets stored in the bowel. This triglyceride can then be released into the blood when another meal is consumed or in response to hormones. How the gut hormone glucagon-like peptide-2 (GLP-2) releases the triglyceride from the gut is not known. The research team in this study is interested in finding out how teduglutide (a degradation resistant form of GLP-2) releases stored triglyceride from the gut by evaluating how blood lipoproteins respond to teduglutide in healthy individuals.


Clinical Trial Description

The lipoprotein response will be performed in 15 healthy individuals recruited by newspaper advertisements. Each subject will be their own control, receiving both placebo and teduglutide, administered on separate occasions. A member of the study team will explain the study in detail on visit 1, and if the individual is interested in participating, informed consent will be obtained and preliminary screening will occur on visit 2. On visit 3 & 4 participants will receive a high fat liquid meal after an overnight fast. Hourly blood samples will be taken for 5 hours, followed by randomized assignment to receive either subcutaneous placebo or teduglutide at visit 3 and the opposite treatment at visit 4. Following the injection, blood samples will be taken every 15 minutes for the first hour and every 30 minutes for the subsequent 3 hours. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03422666
Study type Interventional
Source University Health Network, Toronto
Contact
Status Completed
Phase Phase 2/Phase 3
Start date September 21, 2018
Completion date December 1, 2021

See also
  Status Clinical Trial Phase
Completed NCT03793985 - Compare the Pharmacokinetics and Safety of CKD-391 With Co-administration of D086 and D337 Phase 1
Recruiting NCT03947866 - Ezetimibe-Rosuvastatin Evaluation Study
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Completed NCT04516291 - A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70) Phase 2
Completed NCT04701775 - Effect of Different Probiotic Strains in Hypercholesterolemic Patients N/A
Completed NCT03632668 - Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072 Phase 1
Completed NCT03534661 - L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release Phase 2/Phase 3
Completed NCT00536796 - Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets N/A
Completed NCT03643705 - A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention N/A
Recruiting NCT04560296 - Community-based E-Health Program for Older Adults Living With Chronic Diseases N/A
Terminated NCT04073134 - The CHORAL Flow Study Phase 4
Recruiting NCT05103254 - Bempedoic Acid Pregnancy Surveillance Program
Not yet recruiting NCT05015348 - Effects of Omega-3 PUFA on Lipids, Inflammatory Factors and Body Composition in Patients With Hyperlipidemia N/A
Active, not recruiting NCT05082350 - Nutritional Intervention With Black Garlic N/A
Not yet recruiting NCT04398771 - To Evaluate Safety and Effectiveness of RovatitanTab.
Not yet recruiting NCT04064281 - The Healthy Cantonese Diet on Cardiometabolic Syndrome N/A
Recruiting NCT06257641 - Impact of the Mediterranean Diet on Patients With Psoriasis N/A
Completed NCT03690778 - The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers. Phase 1
Completed NCT04354987 - Compare the Pharmacokinetics and Safety of CKD-391 Phase 1
Completed NCT03337308 - A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy Phase 3